[Skip to Content]
[Skip to Content Landing]
Views 406
Citations 0
Research Letter
April 2018

Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors

Author Affiliations
  • 1Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
  • 2Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
  • 3Institute for Evaluative Clinical Sciences, Toronto, Ontario, Canada
  • 4Department of Oncology, Monash Health and Monash University, Melbourne, Australia
JAMA Oncol. 2018;4(4):583-585. doi:10.1001/jamaoncol.2018.0024

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are widely heterogeneous malignant abnormalities.1 Their natural history is poorly described, with little understanding of recurrence patterns. Surveillance for resected GEP-NETs may include clinical review, laboratory tests, and numerous medical and nuclear imaging modalities. These modalities can increase patient anxiety, may be associated with potential harm (eg, exposure to ionizing radiation), and have not been shown to improve outcomes. Current guidelines vary widely in recommendations, reflecting the lack of data.2,3 Information on the natural history and recurrence of the disease may improve patient-centered follow-up of this population. We hypothesized that GEP-NETs may recur over a longer time course compared with other gastrointestinal malignant abnormalities.